An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Ibrance

Chemical Namepalbociclib
Dosage FormCapsule (oral; 75 mg, 100 mg, 125 mg)
Drug ClassKinase inhibitors
SystemFemale reproductive
CompanyPfizer Inc.
Approval Year2015

Indication

  • For the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ibrance (palbociclib) Prescribing Information 2019Pfizer labs, NY, NY
Document TitleYearSource
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer. 2020NICE
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.2017NICE
Document TitleYearSource
Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis. 2020Medicine
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.2020Expert Review of Anticancer Therapy
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. 2019The Lancet Oncology
Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.2017Breast Cancer Research and Treatment
Document TitleYearSource
NCCN guidelines updates: Breast cancer.2018Journal of the National Comprehensive Cancer Network
Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline.2016Journal of Clinical Oncology